Dosage optimization for reducing tumor burden using a phenotype-structured population model with a drug-resistance...

Area of Science:

• Oncology
• Mathematical Biology
• Pharmacology

Background:

• Drug resistance is a major challenge in cancer therapy.
• Olaparib is a targeted therapy for ovarian cancer, but resistance can develop.
• Understanding resistance mechanisms is crucial for optimizing treatment.

Purpose of the Study:

• To investigate the evolution of cancer drug resistance using a fitness landscape model.
• To integrate pharmacokinetic (PK) modeling with resistance evolution to determine optimal drug dosages.
• To identify strategies for long-term tumor reduction and overcoming resistance to olaparib.

Main Methods:

• Employed a phenotype-structured population model based on the fitness landscape concept.
• Fitted the model to experimental data for olaparib in ovarian cancer.
• Incorporated pharmacokinetic (PK) modeling to simulate drug concentration over time.
• Derived a mathematical formula to guide dosing strategies.

Main Results:

• The study elucidated how drug administration impacts the cancer cell fitness landscape.
• Tracked the evolution of drug resistance within a cancer cell population.
• Identified that maximizing variation in plasma drug concentration may reduce resistance.
• Found potential for improved outcomes with lower-than-label drug doses.

Conclusions:

• Combining PK and drug resistance evolution modeling offers a novel approach to cancer treatment design.
• Optimized dosing strategies, potentially involving lower doses with varied concentrations, could enhance treatment efficacy.
• This integrated modeling approach may pave the way for improved cancer drug regimens.
• Further research is needed to validate these findings and refine treatment protocols.